GlassScriptPhysician profile
Mohammad Babar Yousaf
NPI 1689731622
$34,240.04
in general payments reported to CMS, 2019-2025
39 companies · $1,552 in 2025
The $1,552 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,477 · 2020: $6,263 · 2021: $7,678 · 2022: $12K · 2023: $3,522 · 2024: $1,856 · 2025: $1,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,414 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,401 · Travel and Lodging: $106 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,414.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,401.00 |
| Travel and Lodging | $106.25 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $21,998.36 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,950.12 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,735.97 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,683.24 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $858.58 | 2019-2025 | Jardiance |
| Pfizer INC. | $830.60 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $582.72 | 2019-2024 | Camzyos, Eliquis |
| Novo Nordisk INC | $546.16 | 2022-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $462.17 | 2020-2024 | Farxiga, Brilinta, Wainua |
| Sanofi-Aventis U.S. LLC | $411.25 | 2019-2023 | |
| Amarin Pharma, INC. | $389.04 | 2019-2022 | |
| Boston Scientific Corporation | $352.08 | 2019-2025 | Wolverine Coronary Cutting Balloon, General - Balloon Catheters, Avvigo Guidance System |
| Merck Sharp & Dohme LLC | $303.18 | 2021-2024 | Verquvo |
| Abbott Laboratories | $298.67 | 2019-2023 | Confirm Rx, Jot Dx |
| Abbvie INC. | $245.20 | 2021-2025 | Vraylar |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Yousaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.